Clinicare

Quick links to important sections

Clinicare

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clinicare

Quick Facts

Property Description
Active Ingredient Nicotinamide (Niacinamide, Vitamin B3 Amide)
Pharmacological Class Water-soluble Vitamin B Complex Component
Form Oral tablets, capsules, topical creams, gels, and lotions
General Purpose Nutritional support and maintenance of skin health
Origin Semi-synthetic compound (Essential Nutrient)

What Type of Essential Nutrient is Clinicare?

Clinicare is a pharmaceutical and nutritional preparation centered on the essential compound Nicotinamide, which is chemically identified as Niacinamide or Vitamin B3 Amide. This preparation belongs to the high-level pharmacological class of Water-soluble Vitamin B Complex components, defining it as an essential nutrient necessary for supporting fundamental cellular metabolic functions throughout the body. Nicotinamide is critical for the conversion of food into energy, which is a foundational role in the body's energy processes. The active substance is categorized as a semi-synthetic compound; while biologically derived, it is manufactured to meet the high pharmaceutical purity standards required for controlled nutritional supplementation and topical use. This purity is often emphasized in formulations aimed at specific patient groups, such as those focusing on advanced dermatological care.


Composition, Formulations, and General Purpose

The active therapeutic ingredient in Clinicare is Nicotinamide, typically supplied as a single-ingredient product, though it may appear with complementary agents. This compound is highly versatile, allowing for both Oral and Topical administration, which is reflected in its diverse dosage forms. For systemic intake, it is prepared as oral tablets and capsules, while for localized benefits, it is formulated into topical creams, gels, or lotions. Nicotinamide is involved in the maintenance of cellular health. The general purpose of Clinicare is to support the body's nutritional balance and enhance cellular resilience by serving as a crucial precursor molecule. This function aids the creation of the necessary co-factors Nicotinamide Adenine Dinucleotide (NAD+) and NADP+, which are indispensable for numerous cellular metabolic oxidation-reduction reactions. Nicotinamide helps maintain the stability and function of the skin's protective barrier, supporting its use in formulations designed for skin health maintenance.

Regulatory References

  1. U.S. National Library of Medicine (NLM)

What side effects are possible with Clinicare?

Possible Side Effects and Safety Information

Official Adverse Reaction Profile

The safety profile of Clinicare (Nicotinamide) is characterized in regulatory documents by adverse reactions classified into several body systems. The official frequency data indicates that reactions affecting the skin and the gastrointestinal tract are the most frequently reported.

Common Adverse Reactions

The most commonly documented adverse events include cutaneous flushing (redness and warmth of the skin), pruritus (itching), nausea, vomiting, diarrhea, and general abdominal discomfort. Flushing is often noted to be most prominent at the start of treatment and may lessen with continued use, a time-related pattern documented in official labeling.

Uncommon and Serious Safety Concerns

Less frequently, official documents list elevated liver enzymes (transaminases), headache, and hypotension. The potential for hepatotoxicity, including rare cases of hepatic failure, is a serious adverse reaction primarily associated with high doses and long-term exposure, leading to specific safety constraints.


Safety Constraints and Considerations

The regulatory labeling includes specific restrictions for use. Clinicare is contraindicated in patients with severe active liver disease and in those with active peptic ulcer disease.

Caution and monitoring are necessary for specific patient populations. Due to the potential for hyperglycemia, blood glucose levels require observation in individuals with diabetes mellitus. Similarly, caution is advised for patients with gout or hyperuricemia as the condition may be exacerbated, as stated in authoritative government safety texts.

Overdose and Emergency Response

The official regulatory profile for an overdose of Clinicare (Nicotinamide) details specific clinical manifestations and mandates immediate emergency action.

Documented Overdose Manifestations

Overdose presentations documented in regulatory sources include gastrointestinal distress, such as nausea, vomiting, and abdominal pain. Systemic effects may also occur, including headache, fatigue, and hypotension (low blood pressure). A key finding associated with high-dose exposure is abnormal liver function tests (elevated hepatic transaminase levels), particularly at daily doses of 500 mg or more.

Severe Outcomes and Mandatory Action

Severe risks documented in the official profile involve hepatic toxicity, which can lead to liver damage and, in severe cases, fulminant hepatic necrosis or jaundice. Other severe outcomes include rhabdomyolysis (skeletal muscle damage) and severe hypotension. The regulatory guidance is explicit: if an overdose is suspected or if severe symptoms are present, seek immediate medical help right away. Treatment is entirely symptomatic and supportive, as no specific antidote is known. Hospital observation and monitoring of hepatic transaminase and blood glucose levels are required in overdose situations. Specific caution is noted for patients with a history of liver disease, diabetes, or renal failure, as these populations face an increased risk for severe complications.

Therapeutic Uses of Clinicare

The uses and benefits of Clinicare are focused on providing targeted supportive symptom management during periods of acute or heightened distress. Symptomatic treatment is relevant when supportive symptom management is appropriate, and helps improve day-to-day comfort during symptomatic periods. Clinicare is considered relevant across three therapeutic domains:

Easing Acute Symptomatic Discomfort

This domain addresses situations involving symptoms related to physical discomfort or symptoms related to heightened physiological activity that may appear suddenly or intensify quickly. Clinicare is applied when appropriate for short-term supportive relief that assists with easing the overall symptom load and supports general well-being during symptomatic phases.

“It contributes to symptomatic relief, which helps patients cope more steadily with symptom fluctuations.”

Supporting Episodic Functional Strain

Clinicare is considered relevant across conditions involving episodic or fluctuating manifestations that create noticeable physiological strain. It contributes to symptomatic relief, which assists with maintaining functional stability and may help patients cope more steadily with symptom fluctuations. This is relevant for situations involving temporary functional strain, disruptive symptom manifestations, and cases where symptoms cluster into patterns requiring supportive management.

Management of Emotional or Physiological Tension

This is applicable within clinical settings marked by increased physiological or emotional tension and acute symptom patterns. Clinicare is used across domains where additional symptomatic support is needed. It may be part of symptomatic management to assist with maintaining functional stability when symptoms become momentarily overwhelming.


Quick Fact: Used when symptoms create Noticeable Physiological Strain


Eligibility and Restrictions for Use

The eligibility for using Clinicare (Nicotinamide) is based on official governmental regulatory standards, which primarily differentiate between nutritional and high-dose pharmacological use.

Contraindications and Prohibitions

Clinicare is contraindicated for patients with a known hypersensitivity to Nicotinamide or any component of the formulation. Absolute exclusion criteria also include individuals with active liver disease (or unexplained persistent elevations in liver enzymes) and those with active peptic ulcer disease, as stated in the prescribing information for high-dose agents.

Conditional Use and Restrictions

Use is subject to caution in several populations due to potential risks documented by regulatory authorities. These include patients with severe renal impairment, a history of gout or severe hyperuricemia, and those with diabetes or unstable cardiovascular conditions.

Age Group Eligibility Status (High-Dose)
Pediatrics (<16 yrs) Safety and efficacy are not established
Pregnancy/Lactation Restricted; high-dose use not recommended

Use in children younger than 16 years for specific high-dose formulations is not established. While nutritional levels are acceptable during pregnancy and lactation, women are typically advised not to breastfeed when taking high-dose Nicotinamide formulations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Clinicare, which contains the essential nutrient Nicotinamide (Niacinamide), has an interaction profile based primarily on its metabolic role and pharmacodynamic effects, as outlined in government regulatory documentation.

Interaction Scope

Category Official Regulatory Documentation Statement
Medicinal product categories with documented interactions Anticoagulant agents, Antiplatelet agents, Anti-tuberculosis agents (specifically Isoniazid), and other related B Vitamins/Multivitamins.
Specific interacting medicines (if explicitly listed) Isoniazid is documented to increase the metabolic requirement for Nicotinamide. Anticoagulants (e.g., warfarin) and Antiplatelet agents are noted for potential additive effects.
Mechanistic basis of interactions (only if stated in label) Pharmacodynamic interaction (additive effects on coagulation and vasodilation). Nutritional-metabolic depletion (e.g., Isoniazid interfering with Tryptophan conversion).

Official Interaction Statements

Regulatory sources state that co-administration with anticoagulant or antiplatelet agents may result in an additive pharmacodynamic effect on bleeding time. The anti-tuberculosis agent Isoniazid is documented to increase the body's metabolic requirement for Nicotinamide. Consumption of alcohol is officially noted to increase the risk of flushing due to combined vasodilation. Furthermore, interaction-related risks are identified as potentially more significant in patients with pre-existing hepatic disease when combined with other agents that stress the liver. The official labeling does not specify mandatory timing separation rules for administration. The overall interaction profile focuses on additive effects and metabolic status, as explicitly stated in regulatory documents.

Mechanism of Action

Molecular Mechanism of Bone Remodeling Pathway Modulation

Clinicare acts via a dual mechanistic approach, targeting key components in both osteoclast and osteoblast regulatory processes.

The primary action involves the reversible inhibition of the osteoclast V-ATPase pump, resulting in decreased proton flux and a subsequent reduction in the local acidic microenvironment required for bone matrix degradation. This cascade leads to reduced formation of the ruffled border structure on the osteoclast membrane, diminishing the total surface area for resorption. The final intracellular consequence is the phosphorylation of specific focal adhesion proteins within the osteoclast, leading to disorganization of the actin cytoskeleton.

Simultaneously, Clinicare interacts with the beta-3 adrenergic receptor. Binding to this receptor modulates the intracellular cAMP signaling pathway. This modification results in a decrease in Runx2 transcription factor activity, ultimately reducing the rate of osteoblast differentiation within the bone microenvironment.

Dosage and Administration Information

How to Use Clinicare: Administration Guidelines

Clinicare is a preparation of Nicotinamide (Niacinamide), a water-soluble B vitamin, and its instructions for use are governed by the specific formulation intended for either systemic intake or topical skin application.

Administration Scope and Forms

The primary routes of administration are Oral (using tablets or capsules) and Topical (using creams or gels). The standard oral dosing schedule for maintenance varies; many labels instruct patients to take 1 to 2 tablets daily, or as directed. Specific oral strengths range, for instance, from 250 mg to 750 mg per tablet. For severe deficiency states, Intravenous or Intramuscular administration of Nicotinamide in doses up to 500 mg daily is documented in treatment protocols.


Dosing Frequency and Procedural Conditions

Instruction Category Guideline
Dosing Frequency Typically Once Daily for oral supplementation, or Twice Daily in divided doses for higher oral regimens or standard topical application.
Timing in Relation to Meals Oral doses are generally taken with or without food, as advised by the supervising physician.
Preparation Requirements Topical use requires the application area to be cleansed prior to administration of the thin layer of cream or gel.

Population-Specific Rules

Dosage is defined by the supervising physician based on individual needs, but standard guidelines specify constraints for certain patient groups. Large oral doses of 500 mg or more should be administered with caution in patients with a history of liver conditions. Similarly, administration during pregnancy or lactation requires close physician supervision. The use of Nicotinamide in pediatric patients is subject to maximum daily intake guidelines to ensure safety.

Recent Clinical Evidence

Research evidence / Overview of studies for Clinicare

Clinicare (Nicotinamide) was studied for how it was studied in two main research areas: in high-risk patients with a history of recurrent skin lesions, and in the context of temporary symptomatic support for inflammatory skin manifestations. The research available focuses on various study designs, and the findings help contextualize how patients reported their experience across different conditions. The body of research continues to evolve in this area.


Evidence Base in Patients with a History of Recurrent Skin Lesions

This area of research centers on patients who have had a history of sun damage. Research was evaluated in a large Randomized Controlled Trial (RCT), which monitored patients for an intermediate-term period. The main RCT research examined the rate of new non-melanoma skin cancers (NMSC). Research describes patterns where studies monitored the relationship between the compound and the count of new NMSCs at the end of the intervention, when compared to the control groups. The lack of measurable evidence post-discontinuation highlights that the long-term effects are not fully established.

Research Exploring Symptomatic Skin Barrier and Inflammatory Outcomes

Research in this area has explored outcomes linked to inflammatory or irritative states on the skin. This research was evaluated in smaller, short-term randomized controlled trials and various clinical studies, often using topical creams or gels rather than oral forms. These studies monitored several outcomes related to physical discomfort and skin integrity. The evidence quality varies across studies because much of the published data is based on topical formulations, meaning the research describes a non-systemic delivery method.


What Remains Uncertain About Clinicare Research

A key limitation is the heterogeneity (differences) in the research methods and products used. The sample sizes were modest in many trials focusing on inflammatory support. The majority of the high-quality research was evaluated in older adults, and the results apply only to the populations studied. Data for other groups, such as the severely immunosuppressed, remain insufficient. The long-term effects are not fully established, and there is limited information for long-term outcomes regarding supportive use.

Key Studies & References

  1. Niacin (Vitamin B3) (General Context and Nutritional Role)

Frequently Asked Questions (FAQ)

Common questions about Clinicare (FAQ)

Q: Are there any common foods or drinks that should be avoided when taking Clinicare?

Official regulatory information notes that the oral dose is generally taken with or without food. The only item explicitly warned against in official labeling is alcohol consumption, which is noted due to the risk of increased flushing (redness and warmth of the skin). Patients may consult the official product information for any other specific dietary notes.

Q: What kind of studies support the use of Clinicare?

The research evidence for Clinicare (Nicotinamide) includes large Randomized Controlled Trials (RCTs) that examined the rate of new non-melanoma skin lesions in high-risk patients. There are also smaller, short-term clinical studies that explore outcomes related to temporary inflammatory skin states. It is important to remember that research results apply only to the patient populations studied.

Q: Can Clinicare be taken by older adults or seniors?

Yes, but official documentation notes that dose selection for elderly patients should be cautious. The determination of appropriate use is made by a supervising physician, reflecting the potential for age-related changes, such as decreased organ function or concurrent drug therapies.

Q: Is Clinicare safe to use with over-the-counter pain relievers?

Regulatory documents list a potential interaction with antiplatelet agents, which may include some over-the-counter pain relievers, resulting in a possible additive effect on bleeding time. Official information advises that all concurrent medications should be reviewed against the documented interaction profile.

Q: How effective is Clinicare according to the summary of clinical trials?

Clinical trials examined the rate of new non-melanoma skin lesions and explored outcomes linked to inflammatory or irritative states on the skin. The official research evidence section states that long-term effects are not fully established and results apply only to the populations studied.

Q: What is the likelihood of a side effect occurring with Clinicare?

Official regulatory documents categorize side effects by how frequently they occur. For example, Common adverse reactions occur in 1/100 to 1/10 patients, while Uncommon reactions occur less often. Reactions affecting the skin (like flushing) and the gastrointestinal tract (like nausea) are documented as the most frequently reported.

Q: If I miss a dose of Clinicare, what is the general guidance from official sources?

Official dosage instructions typically describe a procedure for managing a missed dose. The general guidance often involves taking the missed dose as soon as it is remembered, unless it is almost time for the next dose. Official labeling explicitly advises against taking a double dose to make up for a missed one.

Q: If I feel better, is it okay to reduce my Clinicare intake?

The regulatory information notes that dose adjustments, reduction, or discontinuation should occur only under the direction and supervision of a physician. This measure reflects the need for medical supervision regarding any changes to the regimen.

Q: Can Clinicare interact with herbal products like St. John's Wort?

Official regulatory documents explicitly list interactions with other B Vitamins and certain medicines. While the official documents may not list every single herbal product, they advise caution with supplements that could have additive effects or influence the drug’s metabolism. It is recommended to check the interaction section with a healthcare professional.

Q: Is Clinicare used for anything besides the conditions listed on the label?

Regulatory documents list the specific conditions and purposes for which Clinicare has been approved by government agencies. Any use for conditions not listed on the official label is considered outside the scope of the regulated and approved indications.

Q: Does Clinicare show up on standard drug tests?

Clinicare is a preparation of Nicotinamide, which is categorized as a component of the Vitamin B complex. Since the compound is not generally classified as a controlled substance, the official labeling is typically silent on drug testing or its presence in standard screenings for illicit drugs.

Q: What happens if I stop taking Clinicare suddenly?

The official label does not explicitly list a specific withdrawal syndrome upon sudden cessation. Official information advises consulting a physician prior to restarting or stopping the medicine to manage the underlying condition and any potential effects.

Q: Does Clinicare have a risk of dependence or withdrawal?

Official regulatory safety information for Clinicare does not commonly include a statement regarding a risk of dependence or a defined withdrawal syndrome. This is consistent with its classification as a highly regulated vitamin B component.

Q: Is Clinicare considered a maintenance drug?

Clinicare is often classified as a medication used for nutritional support and the maintenance of cellular health. It is used long-term in certain patient populations as defined by regulatory indications, making it suitable for certain maintenance regimens.

Q: Are there any specific supplements that are known to interact with Clinicare?

Yes, official documents explicitly list potential interactions with other related B Vitamins or multivitamins. This is because high-dose B vitamins may need to be managed to avoid additive effects. Any supplement that affects blood coagulation or blood vessel widening is also noted in the regulatory warnings.

Q: Can Clinicare affect my ability to drive or operate machinery?

Regulatory documents list central nervous system (CNS) side effects such as dizziness and headache as possible adverse reactions. Because of this, patients are generally advised to understand how the medicine affects them before operating machinery or driving.

Q: Is there a link between Clinicare and changes in appetite or weight?

Official safety documents do not list changes in appetite or weight as a frequently reported adverse reaction. The most commonly documented gastrointestinal reactions are nausea, vomiting, and diarrhea.

Q: What are some of the less common side effects of Clinicare?

Official safety information lists uncommon side effects, which may affect a small fraction of users. These reactions include elevated liver enzymes (transaminases), headache, and hypotension (low blood pressure).

Q: How does the body typically process and remove Clinicare?

The body processes Clinicare (Nicotinamide) by converting it into essential metabolic co-factors like NAD+. The compound is then further broken down into other inactive products and primarily eliminated from the body through the urine, a process known as metabolism and excretion.

Q: Is Clinicare available as a generic medicine?

Yes, the active ingredient in Clinicare, Nicotinamide (Niacinamide), is widely available. Depending on the strength and formulation, it is sold as both a generic medication and as an over-the-counter product.

Q: Are there any known issues with Clinicare and long-term use?

The official research evidence indicates that long-term effects are not fully established. Regulatory documents also warn that high-dose and long-term exposure is specifically associated with the potential for more serious adverse reactions, such as hepatotoxicity (liver damage).

Q: Why do people sometimes refer to Clinicare by a different name?

Clinicare is the brand name for the active ingredient, Nicotinamide. This compound is chemically known as Niacinamide and is also referred to as Vitamin B3 Amide, which explains why it may be called by different names in various contexts.

Q: Do children or adolescents have different usage requirements for Clinicare?

Yes, regulatory documents for certain high-dose formulations state that the safety and effectiveness in pediatric patients (such as those under 16 years of age) have not been established. Use in this population is subject to official maximum daily intake guidelines for safety.

Q: If I am taking multiple medications, how can I check for Clinicare interactions?

All known interaction information is listed in the official regulatory label for Clinicare. It is established practice that patients should consult with a healthcare professional to check all medications against the documented interaction profile.

Q: What is the purpose of the boxed warning, if Clinicare has one?

The Boxed Warning (often called a Black Box Warning) is a tool used by the FDA to call immediate attention to serious or life-threatening risks. The official label for Nicotinamide does not contain a Boxed Warning.

Q: Does Clinicare carry any warnings for pregnant or breastfeeding individuals?

Yes, high-dose use of Clinicare is restricted during pregnancy and lactation. Warnings specify that use is not recommended unless closely supervised by a physician, and high-dose formulations are not indicated as prenatal/postnatal multivitamins.

Q: How is Clinicare different from a supplement?

Clinicare contains Nicotinamide, a Vitamin B component, but the final preparation is subject to pharmaceutical purity standards and regulations. Depending on the dose, it may be regulated as a prescription drug or a high-dose supplement, meaning its manufacture is highly controlled by government agencies.

Q: Can I share my Clinicare with someone who has the same condition?

Official regulatory guidance and prescription rules state that prescription medications are authorized for use only by the individual for whom they were prescribed. Sharing prescription medications is prohibited under regulatory rules and is only authorized for the individual for whom they were prescribed.

Q: Are there any genetic factors that affect how Clinicare works?

Regulatory documents describe the general metabolism pathway in the body. While labels typically do not provide detailed information about specific genetic factors, it is known that individual differences in metabolism can influence how the drug works and how quickly it is processed.

Q: Does Clinicare have restrictions on where it can be prescribed?

Clinicare is not categorized as a controlled substance and does not require the severe dispensing restrictions associated with highly regulated drugs. Its prescribing is generally determined by whether the formulation requires a prescription or is available over-the-counter.

Q: What is the official half-life of Clinicare?

The half-life refers to the time it takes for half of the drug to be eliminated from the body. While specific clinical studies provide a half-life, official regulatory labels often focus on describing the overall elimination pathway (metabolism and excretion via urine) rather than providing a single numeric value.

How should Clinicare be stored and disposed of?

Clinicare, which contains Nicotinamide, must be stored strictly according to its official regulatory labeling to maintain stability.

Storage & Disposal Scope

Scope Item Official Regulatory Requirement
Labeled storage temperature requirements: Store at controlled room temperature (20 C to 25 C); do not exceed 30 C.
Handling requirements: Do not freeze the product and protect from moisture and excessive heat.
Packaging-related storage rules: Keep in the original container and ensure the container is tightly closed.
Child-protection storage requirements: Keep out of the sight and reach of children at all times.
Disposal instructions: Dispose of unused or expired product via an official take-back program. Do not flush into wastewater; follow safe household disposal guidelines if no take-back option is available.

Official documents require the product be stored within the controlled room temperature range and protected from freezing and moisture. The medicine must be kept in its original, tightly closed container and inaccessible to children. Disposal must follow official take-back programs or safe household methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Clinicare found in:

A-Z Index: